Table 5. Type of Postneoadjuvant Systemic Therapy by Type of Surgery.
| Type of therapy | No. (%) | Difference (95% CI)a | |
|---|---|---|---|
| Arm A: ALND (n = 77)a | Arm B: No ALND (n = 74)a | ||
| Carboplatin/cisplatin | 3 (3.9) | 0 (0) | 3.9% (−1.8% to 9.5%) |
| Capecitabine | 10 (13.0) | 10 (13.5) | −0.5% (−12% to 11%) |
| Trastuzumab | 5 (6.5) | 5 (6.8) | −0.3% (−8.5% to 7.9%) |
| Pertuzumab | 1 (1.3) | 1 (1.4) | −0.1% (−3.8% to 3.6%) |
| T-DM1 | 11 (14.3) | 9 (12.2) | 2.1% (−10% to 14%) |
| Checkpoint inhibitors | 2 (2.6) | 0 (0) | 2.6% (−2.3% to 7.5%) |
| Aromatase inhibitors | 36 (46.8) | 41 (55.4) | −8.7% (−26% to 8.6%) |
| GnRH analogons | 4 (5.2) | 7 (9.5) | −4.3% (−14% to 5.4%) |
| Tamoxifen | 6 (7.8) | 8 (10.8) | −3.0% (−14% to 7.6%) |
| CDK4/6 inhibitors | 3 (3.9) | 4 (5.4) | −1.5% (−9.6% to 6.5%) |
| PARP inhibitors | 0 (0) | 1 (1.4) | −1.4% (−5.3% to 2.6%) |
Abbreviations: ALND, axillary lymph node dissection; CDK4/6, cyclin-dependent kinase 4/6; GnRH, gonadotropin-releasing hormone; PARP, poly ADP ribose polymerase; T-DM1, trastuzumab emtansine–DM1.
a
Difference in proportions.